Form 4: MBX Biosciences Director Reports Conversion of Preferred Stock and Purchase of Common Stock

Edward T. Mathers, a director of MBX Biosciences, reports the conversion of Series A and B preferred stock into common stock and the purchase of additional common stock.

Summary

• On September 16, 2024, Edward T. Mathers, a director of MBX Biosciences, reported transactions involving the company's stock.
• The transactions included the conversion of 12,299,854 shares of Series A Convertible Preferred Stock into 1,023,103 shares of Common Stock.
• Additionally, 25,142,840 shares of Series B Convertible Preferred Stock were converted into 2,091,383 shares of Common Stock.
• Mathers also purchased 500,000 shares of Common Stock at a price of $16 per share.
• Following these transactions, the total amount of Common Stock beneficially owned indirectly by Mathers is 3,614,486 shares.
• The reporting person disclaims beneficial ownership of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

Sentiment

Score: 7

Explanation: The transactions reflect a planned conversion of preferred stock related to the IPO and a purchase of common stock, suggesting a positive outlook from the director.

Positives

• The conversion of preferred stock to common stock simplifies the capital structure of MBX Biosciences.
• The purchase of 500,000 shares at $16 per share by a director signals confidence in the company's prospects.

Industry Context

Form 4 filings are standard practice for company insiders to report transactions in their company's stock, providing transparency to investors.

Stakeholder Impact

• The conversion of preferred stock to common stock could impact shareholders by changing the capital structure.
• The purchase of common stock by a director may increase investor confidence.

Key Dates